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Aims To report the longer term outcomes following either a strategy of endovascular repair first or open repair of ruptured
abdominal aortic aneurysm, which are necessary for both patient and clinical decision-making.
Methods
and results
This pragmatic multicentre (29 UK and 1 Canada) trial randomized 613 patients with a clinical diagnosis of ruptured
aneurysm; 316 to an endovascular first strategy (if aortic morphology is suitable, open repair if not) and 297 to open
repair. The principal 1-year outcome was mortality; secondary outcomes were re-interventions, hospital discharge,
health-related quality-of-life (QoL) (EQ-5D), costs, Quality-Adjusted-Life-Years (QALYs), and cost-effectiveness
[incremental net benefit (INB)]. At 1 year, all-cause mortality was 41.1% for the endovascular strategy group and
45.1% for the open repair group, odds ratio 0.85 [95% confidence interval (CI) 0.62, 1.17], P ¼ 0.325, with
similar re-intervention rates in each group. The endovascular strategy group and open repair groups had average
total hospital stays of 17 and 26 days, respectively, P, 0.001. Patients surviving rupture had higher average
EQ-5D utility scores in the endovascular strategy vs. open repair groups, mean differences 0.087 (95% CI 0.017,
0.158), 0.068 (95% CI 20.004, 0.140) at 3 and 12 months, respectively. There were indications that QALYs
were higher and costs lower for the endovascular first strategy, combining to give an INB of £3877 (95% CI
£253, £7408) or E4356 (95% CI E284, E8323).
Conclusion An endovascular first strategy for management of ruptured aneurysms does not offer a survival benefit over 1 year but
offers patients faster discharge with better QoL and is cost-effective.
Clinical trial
registration
ISRCTN 48334791.
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Introduction
Ruptured abdominal aortic aneurysm (AAA) is fatal in over 80% of
cases and operative mortality remains high in those who survive to
undergo repair (42%).1 The majority of patients in Europe, the
USA, and elsewhere is treated with open surgical repair rather than
the less invasive endovascular aneurysm repair (EVAR)1–4 and emer-
gency EVAR is not available, or not always available, in many centres.
Following a small pilot trial,5 three larger European randomized trials
of endovascular vs. open repair of ruptured aneurysms were estab-
lished, with the aim of testing the hypothesis that 30-day outcomes
werebetter aftereitherendovascular repairoranendovascular strat-
egy: observational studies suggest that operative mortality after
emergency endovascular repair is in the range of 16–36%, varying
with haemodynamic stability.3,4 The conventional reporting standard
for surgery is 30-day mortality and all three later randomized trials
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have reported this outcome recently.6–8 In the two smaller trials,
which recruited a limited range of patients, who were fit for open
repair and after CT scan deemed anatomically suitable for EVAR,
30-day mortality (20–25%) was similar in patients randomized to
EVARvs. open repair.6,8 Themuch larger IMPROVE trial, randomized
patients at the point of in-hospital clinical diagnosis, when vascular
teams were alerted, but before a CT scan had confirmed either the
diagnosis or the anatomical suitability for EVAR. Randomization
was to an endovascular strategy (EVAR wherever possible, with
open repair for those anatomically unsuitable for standard EVAR)
vs. open repair. The aimof this trial was to assess the clinical and cost-
effectiveness of a preferential endovascular strategy for the manage-
ment of suspected rupturedAAA.Again therewas no30-day survival
benefit for the endovascular strategy, except perhaps inwomen,with
overall mortality 35%.7
An editorial commentary on the 30-day outcomes of the
IMPROVE trial emphasized correctly thatmodern intensive careper-
mitted more patients to survive to 30 days, with many patients still
being in hospital at 30 days, so that only an assessment of longer
term outcomes, to 90 days and beyond, would provide the requisite
evidence for both clinical and patient decision-making.9 This need for
longer term data also is endorsed by a recent Cochrane review and
the IDEAL recommendations.10,11 To the patients and their families
involved in the design of the IMPROVE trial, the most important
outcome was going home without major complications. Here we
report the 1-year pre-specified outcomes from the IMPROVE trial.
Methods
Trial design
IMPROVE (Current Controlled Trials ISRCTN 48334791) is a multi-
centre trial of unselected patients with an in-hospital clinical diagnosis
of ruptured AAA randomized to either an endovascular strategy of
immediate CT scan and emergency EVAR if possible or to emergency
open repair. Since patients were randomized before knowledge of
whether the aortic anatomy was suitable for EVAR, open repair was
the specified treatment for patients (35–40%) who were anatomically
unsuitable for EVAR in the endovascular strategy group. In the open
repair group, CT scan was not compulsory but was used in 90%. The
trial methods and 30-day outcomes have been published7 and, together
with the studyprotocol, and statistical analysis plan, are available from the
trial web sites www.improvetrial.org; www.imperial.ac.uk/medicine/
improvetrial. Briefly, this trial was conducted in 29 British centres and 1
Canadian centre, with each centre attaining the credentialing criteria ne-
cessary for participation. Patients over 50 yearswith a clinical diagnosis of
ruptured AAA or ruptured aorto-iliac aneurysm were eligible for in-
clusion, and 613 patients were randomized from September 2009 to
July 2013. The trial guidelines for EVAR suitability were aneurysm neck
diameter ≤32 mm, aneurysm neck length≥10 mm, and neck angulation
,608.12 Since the diagnosis of rupture can be difficult,13 CT scans were
reviewed later by experts in a core laboratory. There are no ESC guide-
lines for the management of ruptured AAA.
Randomization
The trial used central telephone computer-generated randomization
(1:1), stratifiedby centrewith variable block size.7 Since thiswas a surgical
trial focusing on mortality there was no blinding.
Outcomes
The principal longer term outcome was all-cause mortality at 1 year
and other 1 year measures included aneurysm-specific mortality,
re-interventions, health-related quality-of-life (QoL), resource use,
disposal (length of hospital stay and the patient-preferred outcome
of discharge home, see Supplementary material online, Table S1),
costs, and Quality-Adjusted-Life-Years (QALYs). We estimate cost-
effectiveness by combining costs and QALYs to report incremental
net benefit (INB). All-cause mortality in the UK was assessed through
data linkage with the Office for National Statistics and locally in
Canada. Trained local coordinatorswere responsible for the collection
of prospective resource use data including re-interventions according
to the trial case record form (during the primary admission and
re-admissions with all interventions within 30 days classified as aneur-
ysm related). The completeness of re-intervention and re-admission
data was verified by monitoring and using an administrative dataset
(Hospital Episode Statistics). The EuroQoL questionnaire (5-dimension
3-level version; EQ-5D), a generic measure of health-related QoL on
a scale anchored at 0 (death) and 1 (perfect health), was administered
at 3 and 12 months to patients discharged following ruptured AAA
repair.14
Detailed resource use and costs within 1 year of randomization were
measured in accordance with international guidelines,15 and reported
from a UK NHS and Personal Social Services perspective16 (see Supple-
mentary material online, including unit costs, Table S2).
Ethical approval was provided by South-Central Berkshire Research
Ethics Committee 08/H0505/173 (England and Wales), Scotland A Re-
search Ethics Committee 08/MRE00/90 (Scotland), and the University
of Western Ontario Health Sciences Research Ethics Board 17698
(Canada). There was a two-stage consent procedure, a brief initial
consent and full post-operative consent. The National Information Gov-
ernance Board ECC 4-03 (f) 2012 approved the collection of data for
date and cause of death for patients without second post-operative
consent.
Statistical analysis
The trial required the recruitment of 600 patients to show a 14% abso-
lute difference in survival between the randomized groups with .90%
power. Analyses were by intention-to-treat, with the principal sensitiv-
ity analysis restricted to the 502 patients with a confirmed diagnosis of
rupture in whom repair was commenced, according to the pre-
specified analysis plan (www.improvetrial.org). The proportion surviv-
ing at 1-year post-randomization was compared between the rando-
mized groups, using a Pearson’s x2 test without continuity correction,
and odds ratios were reported using logistic regression before and
after adjustment for sex, age (continuous measure), and Hardman
Index17 (continuous, a validated scoring system for ruptured AAA).
Kaplan–Meier survival curves were plotted after censoring at the end
of follow-up or at 1 year, whichever came first, for overall and
aneurysm-specific mortality and time to first re-intervention, using
log-rank tests for between-group comparisons. As previously7, we
fitted a complier average causal effects model to estimate the potential
effect of all patients adhering to trial protocol. Gray’s non-parametric
test, accounting for competing risks, was used to compare the cumula-
tive incidence of overall discharge (from index admission hospital and
secondary hospital) and for discharge to home (time to discharge com-
pared withWilcoxon rank-sum test). For pre-specified subgroups (age,
sex, and Hardman index), differences were assessed using logistic re-
gression with a test of interaction; given the multiple tests performed
an interaction test P-value of ,0.01 was required to claim strong evi-
dence of differences between subgroups. The EQ-5D utility index
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score was calculated by combining the EQ-5D health profile of each
patient with health state preference values from the UK general popu-
lation.14 The resultantmeanQoL utility scores at 3 and 12months post-
randomization were contrasted between the randomized groups, with
unpaired t-tests. Quality-Adjusted-Life-Years up to 1 year were calcu-
lated by valuing each patient’s survival time by their QoL at 3 and
12 months according to the ‘area under the curve’ method.18 The
study estimated INBs by valuing incremental QALYs at the recom-
mended threshold for a QALY gain (£30 000) then subtracting the in-
cremental costs from this with conversions into E (£1:E1.23519)
reported (see Supplementary material online, Appendix for details).
Missing data on baseline covariates (Hardman index), QoL, and re-
source usewere addressedwithmultiple imputation20 (see Supplemen-
tary material online Appendix and Table S3). Sensitivity analyses to
explore the robustness of the results to alternative assumptions were
conducted, e.g. different staffing levels for the emergency operation
or varying the unit costs of the EVAR device.
Results
One-year survival data were available for 611/613 patients rando-
mized (Figure 1). Of the 613 patients, 536 had proven AAA
rupture, and repair was started in 502 (see Figure 1). For the 77
patients without AAA rupture, 22 had acute, symptomatic AAA
(with repair in 21), while of the 55 patients with discharge diagnoses
unrelated to AAA 45 had co-existing asymptomatic AAA (mean
diameter 6.9 cm) and 1 further patient had a thoracoabdominal an-
eurysm. Baseline characteristics were similar between the rando-
mized groups7 (see Supplementary material online, Table S4);
overall 480 (78%) were men, with mean (SD) age of 76.7 (7.6)
years, aneurysm diameter of 8.4 (1.9) cm, and admission systolic
blood pressure of 110 (32) mmHg.
After 1 year, 130 (41.1%) of patients in the endovascular strategy
group had died vs. 133 (45.1%) in the open repair group, unadjusted
odds ratio 0.85 [95% confidence interval (CI) 0.62, 1.17], P ¼ 0.325.
Adjusted results and those restricted to patients with ruptured AAA
repairwere similar, with odds ratios 0.86 (95%CI 0.62, 1.21) and 0.86
(0.59, 1.24), respectively. Almost half the deaths, in each group,
occurred within 24 h and the majority occurred within 30 days
(Table 1 and Figure 2A). At 1 year, AAA-related mortality (including
all deaths within 30 days) in the endovascular strategy and open
repair groups, respectively, was 33.9% and 39.3%, unadjusted odds
ratio of 0.79 (95% CI 0.57, 1.10), P ¼ 0.161 (see Supplementary ma-
terial online, Figure S1). The subgroup analysis of 1-year mortality
foundweakevidence that the endovascular strategywasmoreeffect-
ive inwomen than inmen, ratio of odds ratio 0.41 (95%CI 0.18, 0.93),
P ¼ 0.034 (Figure2B).Among rupturedaneurysmpatientswith repair
Figure 1 CONSORT diagram showing flow of patients through the trial. AAA, abdominal aortic aneurysm; rAAA, ruptured abdominal aortic
aneurysm; 23% of ruptured abdominal aortic aneurysmswere juxtarenal with an aortic neck length,10 mm,21 75% infra-renal, and 2% aorto-iliac.
aOne hundred and forty-nine endovascular aneurysm repair and 110 open repair (27 open repairs in patients suitable for endovascular aneurysm
repair, breach of protocol mainly for operational reasons, e.g. endovascular suite in use or inadequately staffed), b210 open repairs and 33 endovas-
cular aneurysm repairs in breach of protocol, mainly for avoidance of general anaesthesia. 1Follow-up pertains to endpoints other than mortality.
^One patient mortality known to 30 days and one patient mortality known to 3 months. Case record form (CRF) captures re-interventions and
re-admissions, and outpatient visits to the trial hospital.
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started, the 1-year mortality was 98/259 (37.8%) in the endovascular
strategy group and 104/241 (43.2%) in the open repair group,
adjusted odds ratio 0.86 (95% CI 0.59, 1.24), P ¼ 0.400. The esti-
mated unbiased causal odds ratio for a trial in which everyone
adhered to the randomized policy was slightly lower: 0.78 (95% CI
0.49, 1.24).
Overall, the time to first AAA-related re-intervention was similar
between the randomized groups, P ¼ 0.701 (log-rank test) (see Sup-
plementarymaterial online, Figure S2) and for the 502 rupturedAAA
patients who underwent repair P ¼ 0.674 (log-rank test) (Figure 3,
Table 1, details with reasons for re-interventions in Supplementary
material online, Table S5). Between 31 days and 1 year, there were
only 11 patients (4.2%, 12 procedures) with re-interventions in
the endovascular group (including 5 endograft related, 1 revision
of iliac limbof open repair, 1 limb ischaemia, and 1 colonic ischaemia)
and 9 patients (3.7%, 13 procedures) in the open repair group
(including 2 for limb ischaemia, 3 colonic ischaemia, 3 for continuing
complications of earlier abdominal compartment syndrome, and
1 axillo-bifemoral bypass). Between hospital discharge and 1 year,
there was only one AAA-related death, following open repair in
the open repair group.
In the endovascular strategy group, 10 patients (3%) were trans-
ferred to a secondary hospital vs. 36 patients (12%) in the open
repair group: at 30 days, 79 patients (13%) remained in hospital
(49/79 in the open repair group). The average times to discharge
from hospital (primary and secondary hospitals) were 17 (endovas-
cular strategy group) and 26 days (open repair group), P, 0.001;
there was an indication of slightly higher cumulative incidence of dis-
charge in the endovascular strategy group, P ¼ 0.114 (Figure 4A).
There was strong evidence that a higher proportion of patients
from the endovascular strategy group were discharged directly
home from the primary hospital, P, 0.001 (Figure 4B).
At 3 months, a higher proportion of patients in the endovascu-
lar strategy group reported ‘no problems’ on the physical health
dimensions (mobility, self-care, and pain) of the EQ-5D QoL ques-
tionnaire, compared to the open repair group (see Supplementary
material online, Table S6). The resultant EQ-5D mean utility
scores were higher in the endovascular strategy vs. the open
repair group; the mean differences for ruptured aneurysm AAA
survivors were 0.087 (95% CI 0.017, 0.158; P ¼ 0.015) and
0.068 (95% CI 20.004, 0.140; P ¼ 0.063) at 3 and 12 months, re-
spectively (Table 2 and Supplementary material online, Table S7).
Average total costs (details in Supplementary material online,
Table S8), which included the provision of both types of repair
at all times, were less in the endovascular strategy (£16 394) vs.
the open repair group (£18 723), with a mean incremental cost
of –£2329 (95% CI –£5489, £922) (Table 2) or –E2617 (95%
CI –E6167, E1036).
The QALY gain at 1 year for the endovascular strategy group was
0.052 (95% CI 20.005, 0.108), with similar results across subgroups
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Table1 Mortality for the 613 randomized patients, and numbers of re-interventions in the 502 ruptured abdominal aortic
aneurysm patients with aneurysm repair started
Variable Missing Endovascular strategy Open repair
Deaths n ¼ 316 n ¼ 297
Within 30 days 0 112 (35.4%) 111 (37.4%)
Before primary hospital discharge 0 115 (36.4%) 114 (38.4%)
Before overall hospital discharge 0 115 (36.4%) 116 (39.1%)
Within 1 year 2 130 (41.1%) 133 (45.1%)
Cause of death 2
AAA 107 (33.9%) 116 (39.3%)
Myocardial disease 4 (1.3%) 0 (0.0%)
Pulmonary disease 6 (1.9%) 4 (1.4%)
Cancer 4 (1.3%) 2 (0.7%)
Stroke and other vascular 7 (2.2%) 8 (2.7%)
Other 2 (0.6%) 3 (1.0%)
Patients with re-interventionsa n ¼ 259 n ¼ 243
AAA-related re-intervention 0 55 (21.2%) 49 (20.2%)
Non-AAA-related re-intervention 0 6 (2.3%) 11 (4.5%)
Number of re-interventions per-persona 0
0 201 (77.6%) 187 (77.0%)
1 42 (16.2%) 38 (15.6%)
2 11 (4.3%) 13 (5.4%)
3+ 5 (1.9%) 5 (2.1%)
aAmong 502 ruptured AAA patients with aneurysm repair started.
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(Table 2 and Supplementary material online, Table S9). When the in-
cremental costs and QALYs are represented on the cost-
effectiveness plane, most (87%) of the estimates are in the quadrant
that designates the endovascular strategy as ‘dominant’, with lower
mean costs and higher meanQALYs (Figure 5). The INB of the endo-
vascular strategy vs. open repair is positive at £3877 (95% CI £253,
£7408) or E4788 (95% CI E312, E9149), a finding robust to a
range of assumptions (see Supplementary material online, Tables S9
and 10, Figures S3 and S5), including increases in operating theatre
staff and varying the costs of the EVAR device from £4000 to
£10,000 (vs. £5700 in the base case) or additional interventions,
Supplementary material online, Figure S5. The probability that the
Figure 2 (A) Kaplan-Meier estimates by randomized group, across all patients (log-rank test p ¼ 0.325) and (B) 1-year mortality odds ratios for
specified subgroups.
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endovascular strategy was more cost-effective was.0.90 at all real-
istic thresholdsofwillingness to pay for aQALYgain (see Supplemen-
tary material online, Figure S4).
Discussion
Following repairof a rupturedAAA, it hasbeenproposed that follow-
up, to 90 days and beyond is necessary for patient and clinical
decision-making.9 After 1 year, this trial has shown no significant sur-
vival benefit at any time-point for an endovascular strategy (using a
standard EVARdevicewhenever anatomically and operationally pos-
sible,with open repair as a default option) vs. open repair. In contrast,
there were gains for the endovascular strategy vs. the open repair
group with respect to patient-preferred outcomes: faster discharge,
more often to home, andQoL and overall the endovascular strategy
was cost-effective.
Shockwith systemic organ damage, rather than type of repair might
result in the very high early mortality after ruptured AAA repair and
manypatients haveprolongedhospital stays. There areotherpotential
reasons why there was no difference in survival between the rando-
mized groups. First, the operative mortality from open repair was
lower than anticipated. Second, we now know that aortic anatomy,
particularly aneurysmneck length, has an important influence onmor-
talityand that thosepatientswhoarenotcandidates for standardEVAR
(40%) have the highest operative mortality, particularly for open
repair, and that those anatomically suitable for EVAR have much
lower mortality after either EVAR or open repair.21 The trial was
designed to be inclusive and consider whether the availability of an
endovascular service would improve the outcome of all patients
with rupture, not just those anatomically suitable for EVAR. So inevit-
ably the endovascular strategy group included a significant proportion
ofpatientswhohadtobetreatedwithopenrepair.Therefore, thefind-
ings suggesting faster recovery in the endovascular strategy group are
notable: shorter overall hospital stay, a greater propensity to be dis-
charged to home, and better early QoL than the open repair group.
The between-group mean differences in QoL, 0.087 (3 months) and
0.068 (1 year), exceed the minimum clinically important difference
of 0.03,22 although at 1 year, the mean difference was not statistically
significant. The absolute EQ-5 utility scores of the endovascular
Figure 3 Time to first re-intervention for the 502 patients with repair of ruptured aneurysm started. Log-rank test P ¼ 0.674.
Figure 4 Hospital discharge (A) Overall time to discharge from
hospital and (B) time to discharge home from primary hospital.
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strategy group at 3 and 12 months (0.76 and 0.78) seemed slightly
higher than those undergoing elective EVAR in the EVAR-1 trial
(0.71 and 0.74, respectively),23 whereas the absolute scores of the
open repair group (0.69 and 0.74) were similar to those undergoing
elective open repair (0.67 and 0.75).23 In addition, in this trial, there
was no evidence of a difference in re-interventions (including those
for endoleaks) at any time during the first year after rupture and the
risk of re-intervention for endoleak seems lower than the 10–23%
range suggested in previous reports:3,24,25 the cost-effectiveness esti-
mates remained robust to sensitivity analyses allowing for additional
interventions. This is in contrast to the findings for elective repair,
where in the first year AAA-related re-interventions were more
common after EVAR and EVAR cost significantly more than open
repair.23
Limitations
First, this was a pragmatic trial and in those with ruptured AAA
EVAR was started in only 58% in the endovascular group (with 27
EVAR-suitable patients receiving open repair for operational
reasons) and 33 patients in the open repair group received EVAR
(primarily because theywere deemedunfit for general anaesthesia).
Secondly, data completion was very good, including questionnaire
responses,26 but any missing data were addressed with multiple
imputation, which assumes that any systematic differences in out-
comes can be explained by the variables included in the imputation
model. Thirdly, there was no adjustment for testing of multiple
hypotheses (except for subgroup analyses) but all reported out-
comeswere pre-specified. Fourthly, we did not adhere to the stand-
ard American guidelines for the reporting of complications and
re-interventions,27 which are designed primarily for elective
surgery. Finally, re-interventions and costs following EVAR for
rupturemay increase after 1 year and all patientswill be followed-up
for 3 years to address this.
Currently, only the Dutch AJAX trial has reported outcomes to
beyond 30 days. There were no between-group differences in
health-related QoL and endovascular repair was found not to be
cost-effective.28 There were important distinctions between the
IMPROVE and AJAX trials, which makes it difficult to interpret
the different conclusions concerning QoL and cost-effectiveness;
notably, the AJAX trial included a narrow range of hospitals and
patients (recruited over many years and with few women), used
aorto-uni-iliac devices (with subsequent femoro-femoral crossover
grafting) for endovascular repair and applied unit costs from a single
centre.
In summary, we present new effectiveness and cost-effectiveness
evidence from a large, well-conducted randomized trial, conducted
in the challenging circumstance of emergency patients requiring an
immediate operation to avoid death. It was based on the randomiza-
tion of unselected patients, including appropriate representation of
women, to optimize the generalizability of the findings and all
centres were accredited for providing EVAR in routine and emer-
gencypractice.Although theendovascular first strategyoffers no sur-
vival benefit for patients with ruptured AAA, at up to 1 year, this
within-trial report suggests that wider provision of emergency endo-
vascular services is likely to be a cost-effective use of national health-
care systems.
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Table 2 Quality-of-life, total costs (£GBP), and cost-effectiveness outcomes up to 1 year
Outcome Endovascular strategy Open repair Mean difference [95% CI]
n Mean (SD) n Mean (SD)
EQ-5Da,b at 3 months for ruptured AAA survivors 168 0.76 (0.24) 150 0.67 (0.32) 0.087 [0.017, 0.158]
EQ-5Da,b at 12 months for ruptured AAA survivors 161 0.77 (0.20) 140 0.71 (0.35) 0.068 [20.004, 0.140]
QALYb,c for all randomized patients 316 0.40 (0.35) 297 0.35 (0.35) 0.052 [20.005, 0.108]
Total costb (£GBP) 316 16 394 (19 543) 297 18 723 (20 599) 22329 [25489, 922]
Incremental net benefitb,d [95% CI] (£GBP) 3877 [253, 7408]
aThe EQ-5D is a QoL measure anchored on a scale that includes 0 (death) and 1 (perfect health).
bTheEQ-5D,QALY, cost, and INB results are reported aftermultiple imputation to addressmissing values. The complete case results are shown in the Supplementarymaterial online,
Table S7.
cTheQALY for all randomized patients assumes that for patients without proven rupture, theQoLwas the same as at baseline for patients included in EVAR 123 (see Supplementary
material online, Appendix for further details).
dThe INB for the EVAR strategy vs. open repair is calculated bymultiplying the difference inmeanQALY by the recommended thresholdwillingness to pay recommended byNICE16
for the UK (£30 000 per QALY) and subtracting from this the incremental cost.
Figure 5 Uncertainty in the mean cost (£GBP) and
Quality-Adjusted-Life-Year differences and their joint distribution
for endovascular strategy vs. open repair.
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